Abstract-The authors describe a family with six patients with muscular dystrophy with a variable course. One is a compound heterozygote for CAPN3 mutations (calpainopathy) and the others have a single CAPN3 mutation. Linkage analysis and sequencing revealed a XK gene mutation (McLeod syndrome). This illustrates the variable phenotype of XK mutations and suggests the possibility that CAPN3 heterozygotes may have their condition caused by nonallelic mutations in other unrelated genes.
Limb girdle muscular dystrophy (LGMD) is a genetically heterogeneous disorder characterized by progressive weakness of proximal girdles. Seventeen genes associated with LGMD have been mapped, 10 autosomal recessive (AR) 1 and seven autosomal dominant (AD). 2 The prevalent form in most populations is LGMD2A (calpainopathy), caused by mutations in the calpain-3 (CAPN3) gene. 1, 3 McLeod syndrome is an X-linked neuroacanthocytosis syndrome with hematologic, neuromuscular, and CNS manifestations with onset usually after the third decade of life that also presents with elevated creatine kinase (CK) levels and subclinical myopathy, although rarely a severe myopathy as well. Hematologic features include acanthocytosis, compensated hemolysis, absent Kx red blood cell (RBC) antigen, and weak antigenicity to Kell RBC antigens. 4, 5 We ascertained a white Brazilian family with six affected men (five brothers and a first-degree onceremoved cousin) who presented an overlapping phenotype between LGMD and McLeod syndrome.
Methods. The proband, IV-1, a 16-year-old boy, was ascertained due to severe proximal weakness in the lower and upper limbs. Onset was at age 10, with rapid progression and confinement to a wheelchair at 17. He had a clinically normal younger brother (IV-2, age 11) and five affected cousins, related through their father (II-1). The parents (I-1 and I-2) were clinically normal and nonconsanguineous.
His youngest affected cousin, a 26-year-old man (III-10, figure) had After informed consent, DNA was isolated from blood by standard methods. Four hundred microsatellite markers spaced at 10-cM intervals, from ABI PRISM linkage-mapping set version 2.5, were analyzed in an ABI 3700 DNA capillary sequencer using GENESCAN and GENOTYPER software (Applied Biosystems). Markers located in chromosome 15 (CAPN3 gene location) and on the X chromosome (XK gene) were typed in all family members.
Three exons and splicing sites of the XK gene were amplified (Patients III-1, III-7, and III-10) as previously described. 4 The 17 exons and splicing sites of the calpain-3 gene were amplified (for Patients III-7, III-10, IV-1, and IV-2) according to Richard et al. 6 Amplicons were sequenced in the MegaBACE Sequencer and analyzed through Bioedit software.
Muscle biopsy specimens were analyzed with standard stains, and protein expression of dystrophin, sarcoglycans ␣, ␤, ␥, and ␦, calpain-3, dysferlin, and telethonin were done using immunofluorescence (IF) and Western blot (WB), as previously described. Results. Muscle biopsy. Proband IV-1 displayed a dystrophic histologic pattern including variation in fiber size, internal nuclei, and discrete perimysial proliferation of connective tissue. Muscle protein analysis showed a normal pattern for dysferlin, the four sarcoglycans, and telethonin but revealed a decrease in the amount of the 94-kd calpain-3 band on WB (data not shown).
The proband's cousins (III-5 and III-7) displayed a variable myopathic histologic pattern. The oldest patient (III-5) showed more severe alterations, great variability in fiber size, internal nuclei, degeneration, and endomysial proliferation of connective tissue. Patient III-7 showed milder alterations, with scattered ghost isolated fibers. In both of them, ATPases in three different pHs showed a preserved proportion of fiber types, but with some groups of type I and II fibers (see figure E-1 on the Neurology Web site at www.neurology.org). Mild neurogenic alterations were also present in III-5 and III-7. Muscle protein analysis showed a normal pattern for all the LGMD-analyzed proteins (calpain-3, dysferlin, the four sarcoglycans, and telethonin) as well as for dystrophin.
DNA and linkage analysis. Screening of the CAPN3 gene confirmed that the Proband IV-1 is a compound heterozygote for two allelic mutations: one null mutation (the Basque common mutation 2362-2363AGϾTCATCT) inherAdditional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 13 issue to find the title link for this article ited from his father and an in-frame 254⌬K deletion inherited from his mother; both disease-causing mutations. 8 Subsequently, we found that all five affected brothers (III-4, III-5, III-7, III-9, and III-10) carried the same 254⌬K deletion in one allele of the CAPN3 gene (inherited from their father), but no mutation was found in the maternal allele. Linkage analysis excluded the possibility that the second mutation lay in the CAPN3 gene and suggested a candidate gene at Xp21 (maximum lod score of 2.10 at ϭ 0 for marker DXS8018). The XK gene was considered a good candidate since patients with mutations in this gene have elevated CK levels and may present with muscle weakness. Indeed, the sequencing of this gene revealed an insertion of nucleotide C at codon 151 of this gene, leading to a premature stop codon at 198, in the five affected brothers, but not in the proband IV-1.
Clinical reevaluation. We reassessed these patients 5 years after the first clinical visit. Besides muscle weakness, already observed in the first neurologic examination, Patient III-10 displayed involuntary choreic movements. In addition, we collected a new blood sample from him and his affected brother (III-4) to look for the presence of acanthocytes, which was confirmed in a low percentage of cells in both patients (data not shown).
Discussion.
McLeod syndrome is a rare disorder with approximately 150 patients reported worldwide. On the other hand, LGMD2A is the most prevalent form of LGMD in many populations, accounting for more than 30% of cases. The mutation found in the XK gene in the present family was previously reported in a 55-year-old Japanese man with hyperCKmia, mild proximal muscle weakness, chorea, and hyporeflexia. 9 Families with affected men displaying X-linked inheritance and a normal dystrophin pattern have been previously reported. 10 Despite no identified abnormality in the dystrophin gene or muscle protein, these patients were diagnosed as probable Xp21 Becker muscular dystrophy (BMD) because the dystrophin and the XK genes lie in the same Xp21 interval. McLeod syndrome should be included in the differential diagnosis of men diagnosed as having BMD or LGMD with elevated serum CK, but no identified mutation or muscle protein abnormalities. Detailed neurologic examination (seeking areflexia in particular), careful blood smear analysis for acanthocytes, and determination of Kx and Kell antigens should be performed to exclude McLeod syndrome.
Several independent studies reported that in approximately 10% of the patients with LGMD, only one mutation was identified in the CAPN3 gene or in other associated AR LGMD. 3, 8 It has often been suggested that the second mutation may lie in the noncoding region of the other allele. We are not aware of other reported patients carrying one mutation in the CAPN3 gene in whom the disease was caused by another unrelated mutation.
Molecular analysis in the present family showed that two affected relatives with a similar phenotype (LGMD) have different genetic disorders, calpainopathy and McLeod syndrome, while brothers carrying the same mutation in the XK gene and heterozygous for CAPN3 presented with widely variable clinical courses. It is possible that the combination of an XK mutation and one CAPN3 mutation causes a disease with an LGMD phenotype, although testing this hypothesis was not possible in this family because all affected men carried both mutations.
The present study suggests that in AR disorders in which the second mutated allele is not identified, it may be important to search for mutations in other neuromuscular disease genes. 
